Purpose
The estimation of therapy efficacy plays a central role in the follow-up process of every patient.
The assessment and alteration of therapy is especially emphasised in oncology area.
This complex decision process requires objectiveness which was achieved by introduction of more quantitative method of interpretation.
Thus,
in order to standardise clinical evaluation,
Response Evaluation Criteria in Solid Tumours (RECIST) was established in 2000 and revised (RECIST 1.1) in 2009 (1).
Therefore,
the measurement and the objective estimation of change in tumour size were introduced in...
Methods and Materials
This study was carried out at Institute for Oncology and Radiology of Serbia.
The sample encompassed 25 patients who were initially diagnosed with colorectal adenocarcinoma and consequent liver metastatic disease.
All patients underwent eight to twelve cycles of chimeric anti-EGFR monoclonal antibody agent therapy combined with other chemotherapeutics.
The study data were comprised of CT examinations performed by Siemens SOMATOM Sensation Open involving contrast-enhanced 3mm-reconstructed images from 5mm thickness.
The study involved portal venous phase images of baseline CT examinations and follow-ups after averagely 25.6...
Results
The study sample was comprised of 10 (40%) females and 15 (60%) males.
Patient’s age at the moment of diagnostic procedure ranged from 30 to 73 years with mean of 57.32 years (SD 9.27).
The longest period between baseline and follow-up examination was 31 weeks while the shortest was 24 weeks,
averagely 25.6 weeks.
The results demonstrated almost perfect agreement in baseline assessment and reassessment of the all three readers (p<0.001) (Table 1).
Similarly,
the applied statistics could not identify disturbances in both series of...
Conclusion
The current study enrolled the patients who suffered from liver metastatic disease.
Approximately,
liver metastatic disease is diagnosed in 25% of all new patients at time of primary diagnoses of colorectal carcinoma while up to a quarter of others would develop liver metastases in the course of the illness (3,
4).
Colorectal carcinoma is acknowledged as the second leading cause of total cancer-related death in the Europe Union and the European Region (5,
6).
In fact,
the majority of deaths related to colorectal carcinoma are...
References
1. Eisenhauer EA,
Therasse P,
Bogaerts J,
Schwartz LH,
Sargent D,
Ford R,
et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer.
2009 Jan;45(2):228-47.
2. Jaffe TA,
Wickersham NW,
Sullivan DC.
Quantitative imaging in oncology patients: Part 1,
radiology practice patterns at major U.S.
cancer centers.
AJR Am J Roentgenol.
2010 Jul;195(1):101-6.
3. Bird NC,
Mangnall D,
Majeed AW.
Biology of colorectal liver metastases: A review.
J Surg Oncol.
2006 Jul 1;94(1):68-80.
4. Liu LX,
Zhang WH,...
Personal Information
Marija Gajic Dobrosavljevic MD,
Radiologist,
Department of Diagnostic Radiology and Oncology,
Institute for Oncology and Radiology of Serbia,
Belgrade,
Serbia.
[email protected]
Jasmina Stevanovic MD,
Radiologist,
Department of Diagnostic Radiology and Oncology,
Institute for Oncology and Radiology of Serbia,
Belgrade,
Serbia.
[email protected]
Petar Milenkovic MD,
Radiology Resident,
Department of Diagnostic Radiology and Oncology,
Institute for Oncology and Radiology of Serbia,
Belgrade,
Serbia.
[email protected]